drugset / Trial / NCT05218642
To Evaluate Efficacy, Safety, and Tolerability of KX-826 in Male Subjects With Androgenetic Alopecia
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The study is a randomized, double-blind, placebo-controlled, parallel group, phase 2 study to evaluate the efficacy, safety and tolerability of KX-826 in male subjects with androgenetic alopecia.
Timeline
- Start
- 2022-01-31
- Primary completion
- 2023-02-13
- Completion
- 2023-02-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KX-826 | Unknown | 2.5 mg | Topical |
| Subject | KX-826 | Unknown | 5 mg | Topical |